Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
Drug eluting stents
FDA approval for new drug-eluting stent
Drug eluting stents : 26 November, 2013
The Promus Premier Everolimus-eluting stent for use in coronary arteries has received approval from the food and drug administration
 
Clinical trials begin on femoral artery drug-eluting stent
Drug eluting stents : 10 October, 2013
A New Zealand hospital has begun clinical trials on the use of the Innova drug eluting stent system for correcting problems in arteries above the knee
 
Clinical trial population for eluting stent system completed
Drug eluting stents : 13 September, 2013
Boston Scientific has reached a key point in its clinical trials for the Synergy eluting stent system for the treatment of atherosclerotic coronary lesions
 
Boston Scientific receives FDA approval for platinum chromium stent
Drug eluting stents : 06 June, 2012
The US Food and Drug Administration (FDA) is providing Boston Scientific regulatory approval of 32 mm and 38 mm lengths for the PROMUS Element Plus Everolimus-Eluting Platinum Chromium Coronary Stent System, the company's next-generation drug-eluting stent (DES) technology.
 
Zilver PTX drug-eluting stent receives Japanese approval
Drug eluting stents : 05 March, 2012
In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) to Japanese patients for the first time, Cook Medical receives PMDA approval to sell the Zilver PTX Drug-Eluting Peripheral Stent in Japan.
 
GI Dynamics receives strategic investment from Medtronic
Drug eluting stents : 11 January, 2010
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, receives a strategic investment from Medtronic, the global leader in medical device technology and therapies designed to treat chronic diseases.
 
Drug eluting stent could reduce need for bypass surgery
Drug eluting stents : 24 September, 2009
The European Union now has access to the Zilver PTX peripheral stent for use with Peripheral arterial disease patients
 
Impressive results for Xience drug eluting stent
Drug eluting stents : 22 September, 2009
Sustained clinical advantages demonstrated during US trials of the Xience V Everolimus Eluting Coronary Stent system from Abbott Vascular
 
Abbott’s event line-up for TCT 2009
Drug eluting stents : 17 September, 2009
A distinguished set of speakers on coronary care have been lined up by Abbott Vascular for the Transcatheter Cardiovascular Therepeutics conference
 
Drug eluting stent approval in China
Drug eluting stents : 15 September, 2009
Approval received by Abbott Vascular for its Xience V Drug eluting stent from the Chinese food and drug administration giving the company access to a very large healthcare market
 
Coronary Stent system launched internationally
Drug eluting stents : 02 September, 2009
Abbott Vascular has gone international with its Xience Prime Drug Eluting Coronary Stent for treating coronary disease
 
Sorin enrols first patient in e-Optima Drug-Eluting Stent registry
Drug eluting stents : 23 September, 2008
Sorin Group has announced the first patient enrolment in the e-Optima registry which is designed to assess the clinical performance of the Sorin Group Optima Drug-Eluting Stent (DES) Carbostent in the treatment of real-world patients in routine clinical practice.
 
Safety profile of Endeavor drug-eluting coronary stent is revealed
Drug eluting stents : 24 October, 2007
A pooled analysis of safety data from Medtronic’s Endeavor clinical programme has affirmed the superior safety of the Endeavor drug-eluting coronary stent compared to the best-in-class Medtronic bare metal stent, Driver.
 
Medtronic’s Endeavor Resolute stent receives CE Mark
Drug eluting stents : 23 October, 2007
Medtronic has received CE Mark approval for the commercial sale of the Endeavor Resolute Drug-Eluting Coronary Stent and will launch the product outside the USA earlier than originally projected.
 
Medtronic reveals 12 month clinical data for Endeavor stent
Drug eluting stents : 22 October, 2007
Medtronic has presented new 12 month data from the Endeavor IV (E-IV) trial during a main-arena plenary session at the world’s leading scientific congress for interventional cardiologists, TCT 2007 (Transcatheter Cardiovascular Therapeutics).
 
Taxus IV study demonstrates long-term results of drug-eluting stent compared to bare-metal stent
Drug eluting stents : 22 October, 2007
Boston Scientific has announced five year and final follow-up data from its Taxus IV clinical trial.
 
Next-generation stent shows improved clinical outcomes in long lesions and small vessels
Drug eluting stents : 22 October, 2007
Boston Scientific has revealed nine month data from the pivotal Taxus Atlas Small Vessel and Long Lesion studies, which evaluate the Taxus Liberte Paclitaxel-Eluting Stent System in complex lesions.
 
Promus and Taxus stents report further safety performance results
Drug eluting stents : 22 October, 2007
Boston Scientific has welcomed results from the SPIRIT III Clinical Trial, which continue to support the proven safety and efficacy of the Taxus Express2 Paclitaxel-Eluting Coronary Stent System and add to the growing body of strong clinical evidence for the Xience V (Promus) Everolimus Eluting Coronary Stent System.
 
Next-generation drug-eluting stent looks set to treat coronary artery disease in the USA
Drug eluting stents : 11 October, 2007
A US Food and Drug Administration (FDA) advisory committee has unanimously recommended Medtronic's Endeavor drug-eluting stent for conditional approval as a treatment for coronary artery disease.
 
New trial evaluates second-generation paclitaxel-eluting stent system
Drug eluting stents : 04 June, 2007
Boston Scientific has welcomed an article in the Journal of American College of Cardiology (JACC) that reviews the Taxus Atlas and evaluates the company's second-generation Taxus Liberte paclitaxel-eluting stent system.
 
Boston Scientific's Taxus Liberte Long Stent receives CE Mark
Drug eluting stents : 24 May, 2007
TheTaxus Liberte Long paclitaxel-eluting coronary stent system from Boston Scientific has received the CE Mark. allowing doctors to treat longer coronary artery lesions with a single stent.
 
Four year follow up analysis data for Taxus DES trial is released
Drug eluting stents : 23 May, 2007
Boston Scientific has announced the four year follow-up data from the Taxus VI clinical trial.
 
New DES study investigates antiplatelet therapy compliance
Drug eluting stents : 23 May, 2007
A new study assesses more than 7,000 patients as part of paclitaxel-eluting coronary stent trial.
 
Medtronic reveals Endeavor Resolute DES nine month clinical trial results
Drug eluting stents : 23 May, 2007
The nine month results from the Medtronic Resolute clinical trial show a low number of adverse cardiac events and no protocol-defined stent thrombosis.
 
Long term data is presented for Medtronic's Endeavor DES
Drug eluting stents : 23 May, 2007
Medtronic has presented long term data from the Endeavor clinical trial programme that reinforces the existing safety and efficacy profile of the Endeavor drug-eluting coronary stent.
 
Spirit clinical trial focuses on DES safety results
Drug eluting stents : 23 May, 2007
Additional data from the Spirit First, II and III clinical trials reaffirms prior safety and and efficacy data for the Taxus Express2 Paclitaxel-Eluting Coronary Stent System and Xience V (Promus) Everolimus Eluting Coronary Stent System.
 
Boston Scientific completes European and Intercontinental phases of world's largest DES registry
Drug eluting stents : 14 May, 2007
Boston Scientific has finalised enrollment in the European and Intercontinental phases (II and III) of its Taxus Olympia registry to bring the number of current patients to more than 23,000.
 
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo